Benzylneopentylketon | 6303-84-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Benzylneopentylketon
• 英文别名: Benzyl-(2.2-dimethylpropyl) keton；4,4-Dimethyl-1-phenylpentan-2-one
• CAS: 6303-84-0
• 化学式: C₁₃H₁₈O
• 分子量: 190.285
• InChiKey: GUGWJSWTOXBXTO-UHFFFAOYSA-N

物化性质

• 沸点：
  58 °C(Press: 0.01 Torr)
• 密度：
  0.942±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-(dibromoboryl)-4,4-dimethyl-1-phenyl-2-pentene 在 sodium hydroxide 、 sodium dihydrogenphosphate 、 双氧水 作用下， 以 正戊烷 为溶剂， 反应 2.0h， 以39%的产率得到Benzylneopentylketon
  参考文献：
  名称：

  Binnewirtz, Ralf-Juergen; Klingenberger, Helmut; Welte, Rainer, Chemische Berichte, 1983, vol. 116, # 4, p. 1271 - 1284

  摘要：

  DOI：

文献信息

• Inhibitors of Protein Tyrosine Kinase Activity
  申请人：Raeppel Stëphane

  公开号：US20110257100A1

  公开（公告）日：2011-10-20

  This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions and ophthalmic diseases, disorders and conditions.

  本发明涉及抑制蛋白酪氨酸激酶活性的化合物。特别是，本发明涉及抑制生长因子受体的蛋白酪氨酸激酶活性的化合物，从而抑制受体信号传导，例如，抑制VEGF受体信号传导。本发明还提供了用于治疗细胞增殖性疾病和条件以及眼科疾病、障碍和条件的化合物、组合物和方法。
• NOVEL AZABICYCLOHEXANES
  申请人：Jain Rajseh

  公开号：US20120165320A1

  公开（公告）日：2012-06-28

  The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof.

  本发明涉及公式I的新化合物，其药学上可接受的衍生物，互变异构体，立体异构体包括R和S异构体，多晶型，前药，代谢物，盐或溶剂的形式。该发明还涉及用于合成公式I的新化合物，其药学上可接受的衍生物，互变异构体，立体异构体，多晶型，前药，代谢物，盐或溶剂的过程。
• Processes and Intermediates for Preparing Fused Heterocyclic Kinase Inhibitors
  申请人：MethylGene Inc.

  公开号：US20130310564A1

  公开（公告）日：2013-11-21

  This invention relates to intermediates for manufacturing fused heterocyclic-type kinase inhibitor compounds, such as thienopyridine-based compounds, particularly at an industrial level.

  本发明涉及用于制造融合杂环型激酶抑制剂化合物的中间体，例如基于噻唑吡啶的化合物，特别是在工业水平上。
• COUMARIN-BASED COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND CANCER
  申请人：Zhu Lei

  公开号：US20110306605A1

  公开（公告）日：2011-12-15

  Compounds including those of the Formula I where X, R 1 , R 2 and subscript t are as defined herein, useful as γ-secretase inhibitors, are provided, as are compositions comprising the compounds, as well as methods for use of the compounds for treating or preventing neurodegenerative diseases, such as, for instance, Alzheimer's disease.

  提供包括公式I中的化合物，其中X，R1，R2和下标t的定义如本文所述，这些化合物作为γ-分泌酶抑制剂有用，提供了包括这些化合物的组合物，以及使用这些化合物治疗或预防神经退行性疾病的方法，例如阿尔茨海默病。
• PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS
  申请人：Raeppel Franck

  公开号：US20120095234A1

  公开（公告）日：2012-04-19

  This invention relates to processes and intermediates for manufacturing fused heterocyclic-type kinase inhibitor compounds, such as thienopyridine-based compounds, and to processes and intermediates for preparing intermediates that are useful in the manufacture of fused heterocyclic-type kinase inhibitor compounds, such as thienopyridine-based compounds, particularly at an industrial level.

  本发明涉及制造融合杂环型激酶抑制剂化合物（例如基于噻吩并吡啶的化合物）的过程和中间体，以及制备有用于制造融合杂环型激酶抑制剂化合物（例如基于噻吩并吡啶的化合物）的中间体的过程和中间体，特别是在工业水平上。